[go: up one dir, main page]

US20020065322A1 - Naphthylsalicylanilides as antimicrobial and antiinflammatory agents - Google Patents

Naphthylsalicylanilides as antimicrobial and antiinflammatory agents Download PDF

Info

Publication number
US20020065322A1
US20020065322A1 US09/969,071 US96907101A US2002065322A1 US 20020065322 A1 US20020065322 A1 US 20020065322A1 US 96907101 A US96907101 A US 96907101A US 2002065322 A1 US2002065322 A1 US 2002065322A1
Authority
US
United States
Prior art keywords
compound
group
meta
substituted
following structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/969,071
Other versions
US6407288B1 (en
Inventor
Robert Coburn
Richard Evans
Robert Genco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/969,071 priority Critical patent/US6407288B1/en
Assigned to RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE reassignment RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EVANS, RICHARD T., GENCO, ROBERT J., COBURN, ROBERT A.
Publication of US20020065322A1 publication Critical patent/US20020065322A1/en
Application granted granted Critical
Publication of US6407288B1 publication Critical patent/US6407288B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Definitions

  • the present invention relates generally to the field of antimicrobial agents. More particularly, the present invention provides novel naphthylsalicylanilides and a method for the use of these compounds as antimicrobial and antiimflammatory agents.
  • Salicylanilide compounds have been identified as potential antimicrobial agents. Previously, some of these agents have been shown to be effective against microorganisms associated with dental plaques.
  • U.S. Pat. No. 4,287,191 discloses 5-acylsalicylanilides which are said to be effective antiseptics against a wide range of microorganisms, especially bacteria and the microorganisms prevalent in dental plaque.
  • these compounds were not found to be effective against antibiotic resistant bacteria such as S.mutans .
  • the general structure of these compounds can be represented by the following formula:
  • Z is a substituted phenyl ring
  • R is a substituted or unsubstituted alkyl or phenyl group
  • X is —CN, —F, NO 2 , —H, lower alkyl or lower haloalkyl.
  • U.S. Pat. No. 4,358,443 discloses 5-alkylsalicylanilides having the same general formula as above wherein R is a substituted or unsubstituted-alkyl or phenyl group.
  • U.S. Pat. No. 4,939,132 discloses 5-sulfonylalkylsalicylanilides as antimicrobials having the same general formula as above wherein R is a substituted or unsubstituted alkylsulfonyl group.
  • the present invention provides novel aroylsalicylanilides.
  • the present invention provides novel 5-naphthylsalicylanilides and describes the antimicrobial effects of these compounds against a wide variety of bacteria. Further, this invention also provides a method of using these compounds for obtaining relief from infections associated with the bacteria.
  • Another object of the present invention is to provide a method for the use of naphthylsalicylanilides as antimicrobial agents.
  • a yet another object of the present invention is to provide a method for the control of periodontal disease.
  • FIG. 1 is a representation of the effect of naphthylsalicylanilides and TMF-12 on the ear weights in a mouse ear inflammation assay.
  • partition coefficient as used herein for the purposes of specification and claims is meant the log 10 P where P is the ratio of the molar concentrations of the compositions of the composition in octanol-water system. Partition coefficient is a measure of the lipophilic character of the compound. A partition coefficient of 4 therefore means that the ratio of the concentration of the composition in octanol to the concentration in water is 10 4 or 10,000 to 1.
  • substituted as used herein for the purposes of specification and claims is meant that one or more hydrogens atoms in the compound is replaced with a carbon and/or nitrogen containing moiety such as, but not limited to, alkyl, O-alkyl, branched alkyl, cycloalkyl (all alkyl groups containing 1-6 carbon atoms), CN, CF 3 , NO 2 , methoxy, phenoxy, benzoyl, phenoxymethyl and combinations thereof.
  • a carbon and/or nitrogen containing moiety such as, but not limited to, alkyl, O-alkyl, branched alkyl, cycloalkyl (all alkyl groups containing 1-6 carbon atoms), CN, CF 3 , NO 2 , methoxy, phenoxy, benzoyl, phenoxymethyl and combinations thereof.
  • the present invention is based on the unexpected observation that 5-naphthylsalicylanilides were observed to be more effective antibacterial agents than the 5-acyl or 5-alkyl salicylanilides disclosed in U.S. Pat. Nos. 4,287,191 and 4,358,443.
  • the compounds of the present invention are encompassed by the following formula (designated herein as Formula 100).
  • W is a substituted or unsubstituted naphthyl ring.
  • the substitution on W includes replacing one or more —H with —OH, alkyl, O-alkyl, branched alkyl, or cycloalkyl, containing 1-6 carbon atoms or combinations thereof.
  • Y is a substituted or unsubstituted phenyl ring or substituted or unsubstituted naphthyl ring.
  • the substitution for Y includes replacement of one or more —H atoms with CN, CF 3 , NO 2 , methoxy, benzoyl, phenoxy, phenoxymethyl or combinations thereof.
  • the compounds of the present invention may be represented by the following formula (Formula 110):
  • Z represents the substitution on the phenyl ring.
  • Z is preferably an electron withdrawing group and desirably is not strongly hydrophilic or water solublizing.
  • Z is independently at each location —H, CF 3 , —CN or —NO 2 .
  • Z is H at each position, the compound is designated herein as NA1.
  • Z is —CF 3 at the meta position, the compound has the following structure:
  • NA1mF The above compound is referred to herein as NA1mF.
  • the ⁇ isomer (attachment at the naphthalene 2-position) of this compound is referred to herein as NA2mF.
  • Z is a —CN group at the meta position, the compound has the following structure.
  • NA1mC This compound is designated herein as NA1mC( ⁇ isomer; attachment at the naphthalene 1-position) or Na2mC ( ⁇ isomer; attachment at the naphthalene 2-position).
  • NA1pC a isomer
  • NA2pC ⁇ isomer
  • Z may be a methoxy, phenoxy, benzoyl or phenoxymethyl group.
  • An example when Z is a phenoxymethyl group is as follows.
  • This compound is referred to herein as NA1 — 3BnOPh.
  • the Z substitution is at both the meta positions.
  • An example of a disubstituted compound is as follows, designated herein as NA1mF2.
  • Y is an unsubstituted or substituted naphthyl ring.
  • An example of a compound when Y is a substituted naphthyl ring is as follows (designated as NA1NpC).
  • the naphthyl group W of the naphthylsalicylanilides of Formula 100 may substituted.
  • An example of such a substitution is wherein a —H is substituted by —OH.
  • NA10HmF This compound is referred to herein as NA10HmF.
  • the compounds of the present invention can be synthesized by a two-step process where the first step prepares the ester to be used for all similar (such as 1-naphthoyl) derivatives with the same aroyl group.
  • the desired anilide is prepared by reacting the ester with the aniline or aniline derivative.
  • An advantage of the compounds of the present invention is that they have unexpectedly higher potency than the salicylanilides described previously (U.S. Pat. No. 4,287,191; 4,358,443 and 4,939,132).
  • the 5-naphthyl groups are connected to the salicylanilides via a carbonyl group.
  • the introduction of the naphthyl group at the 5-position renders them effective against a wide range of bacteria.
  • the compounds of the present invention have been found to be effective against both gram positive and gram negative bacteria.
  • These gram positive bacteria include, but are not limited to, Streptococcus mutans, Streptococcus sanguis, Micrococcus luteus, Streptococcus salivarius, Propionibacterium acnes, Actinomyces viscosus, Staphlococcus aureus, Lactobacillus rhamnosus (casei) 7469.
  • the gram negative bacteria include, but are not limited to, Salmonella, Fusobacterium nucleatum 25586 , Actinobacillus actinomycetemcomitans (Aa) Y4 , Escherichia coli, Porphyromonas gingivalis, Salmonella cholerasuis ( Sal. chsuis ), Bacteroides fragilis and Citrobacter.
  • the compounds of this invention may be incorporated into formulations for topical application.
  • Such applications include, but are not limited to, topical formulations the treatment of infection of mouth, skin, scalp, ear, nose, eyes, vagina and rectum.
  • the infections treated by these compounds includes various disorders including gingivitis and acne.
  • the compounds of this invention may also be used as topical antimicrobial or antiinflammatory agents for veterinary use for the relief of infections in various conditions including gingivitis, conjunctivitis and arthritis.
  • the formulations can be applied to, without limitation, mouth, skin, scalp, ear, nose, eyes, vagina and rectum.
  • the method in accordance with the present invention for the relief of infection or inflammation comprises contacting the affected area with the compounds of this invention in a pharmaceutically acceptable carrier containing alcohols, nonionic or ionic detergent.
  • a carrier base may be selected from the group consisting of petroleum jelly, lanolin, paraffin wax, alkanols and mixtures thereof.
  • a base such as lanolin or petroleum jelly
  • a spreadable formulation is obtained and by using a base such as paraffin wax, a stick for topical application is obtained.
  • the compounds of this invention may also be incorporated into liquid carriers containing alcohols, non-ionic or ionic detergents.
  • ethanol, the non-ionic detergent, Tween 80TM and the anionic detergent, sodium lauryl sulfate (SLS) may be used.
  • the above compounds can be used as antimicrobial or antiinflammatory agents in mammals, particularly humans, by topical application of formulations containing the compounds of the present invention. These compounds can be used, without limitation, in tooth pastes, mouth rinses, soaps, shampoos, skin ointments, skin lotions, eye ointments, eye drops, ear drops, and nasal drops.
  • the drug formulations of the present invention can be used for relief of systemic infections.
  • these compounds can be used with pharmaceutical carriers suitable for delivery of lipophilic drugs such as, but not limited to, liposomal formulations or aerosols.
  • Liposomes are phospholipid vesicles which form closed fluid filled spheres when dispersed in aqueous solutions.
  • Phopholipid molecules are polar molecules having a hydrophilic head toward the aqueous side and two hydrophobic tails made of fatty acid chains. At sufficient concentrations, the phospholipid molecules organize into micells with polar heads point toward the aqueous medium and the fatty acid chains point toward the interior of the micelle.
  • Various types of liposomal preparation techniques are described in U.S. Pat. No. 5,958,449, the disclosure of which is incorporated herein by reference. Liposomes may be delivered via routes such as intravenous, subcutaneous and topical. The liposomes may also be directed to target areas with the use of specific targeting agents such as by incorporating specific recognition molecules in the liposomes.
  • This example illustrates the synthesis of 2-Hydroxy-5-(naphthalene-1-carbonyl)-N-phenyl-benzamide designated herein as NA1 in a two-step process.
  • the reaction vessel was a 500 ml three neck round bottom pyrex flask fitted with a 250 mL addition funnel, thermometer, a reflux condenser, and a stirrer.
  • Aluminum chloride (7.98g, 59.8 mmole) and 225 mL of chloroform were added into the round bottom flask and then this stirred suspension was cooled to 5° C. with an external ice-bath.
  • Phenyl salicylate (5.83 g, 27.2 mmole) and naphthalene-l-carbonyl chloride (4.91 mL, 6.21 g, 32.6 mmole) were combined together with 130 mL of chloroform and added dropwise over a hour and half to the stirred suspension. Upon this addition color changes were observed from colorless to light yellow then dark green and finally to dark brown. The temperature was maintained at 5-15° C. during the addition period. Following the addition the reaction mixture was heated to reflux for 48 hours and then allowed to stand at 22° C. for eight hours.
  • reaction mixture was slowly added to a stirred slurry of 50 mL of crushed ice to which 125 mL of 12N HCl had been added.
  • the organic layer was isolated in a 1-liter separatory funnel and was washed 5 times with distilled water. Purity was checked on TLC (silica gel plate) and the solvent used was 1:1 ratio of CH 2 Cl 2 and hexane. Three spots were observed on TLC, the phenyl ester was on the top and the product spot was in the middle.
  • This embodiment demonstrates the effectiveness of the compounds of the present invention against gram positive bacteria.
  • the MIC's for the compounds were determined by a modified microdilution tube dilution method described in “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically” (National Committee for Clinical Laboratory Standards Approved Standards, 1997, NCCLS document M7-A4). In general the modifications were made because of the unique growth requirements for the fastidious oral organisms and for those bacteria that require anaerobic conditions. Reference is also made to “Methods for Antimicrobial Susceptibility of Anaerobic Bacteria” (National Committee for Clinical Laboratory Standards Approved Standards, 1997, NCCLS document M11-A4).
  • the methods were as follows. Cultures were grown for 18-24hrs (aerobic bacteria) or 48-72 hrs (anaerobic bacteria) in the appropriate medium. For aerobic bacteria full strength brain heart infusion medium (BHI, Difco) was used. For anaerobic bacteria, half strength BHI (18.5 g/L) was supplemented by adding yeast extract (10 g/L), hemin (0.29 mL of a stock solution containing 0.1 g/200 mL dH 2 O) and menadione (15 mL of a stock solution containing 0.15 mL in 30 mL 95o EtOH) was used. Initial cultures were diluted to approximately 1 ⁇ 10 8 CFU/mL for use as an inoculum.
  • BHI brain heart infusion medium
  • Each assay received 10 ⁇ L of the inoculum.
  • the drugs were prepared from a stock solution contained in dimethyl sulfoxide (DMSO) and diluted into the culture medium. Final concentrations of the drugs ranged from 50 to 0.05 ⁇ g/assay.
  • the tests were run in duplicate and were incubated appropriately with regard to oxygen requirements for 24 to 48hrs as required. Anaerobic incubation was an atmosphere of 5% C02, 10% H 2 , with the balance N 2 . The lowest concentration of an antimicrobial agent at which no visible growth is noted was referred to as the MIC.
  • NA1mF, NA1mC, NA2mF, NA2mC, NA1pC, NA1, NA1NpC, NA1pBz, NA10HmF, NA1 — 3BnOPh, NA1mOPh and NA1mF2 have been described above.
  • NA1pBz is a naphthylsalicylanilide of Formula 110 wherein Z is benzoyl at the para position.
  • NA1mOPh has the structure of Formula 110 wherein Z is phenoxy at the meta position and NA1-2mOMe has the structure of Formula 110 wherein Z is —OCH 3 at both the meta positions.
  • TMF-12 is described in U.S. Pat. No. 6,117,859.
  • BPAmF, BPAmC and BBAmF are substituted or unsubstituted alkylsalicylanilides described in U.S. Pat. No. 4,287,191. Their structures are also provided below
  • BPAmF has the following structure:
  • BPAmC has the following structure:
  • BBAmF has the following structure:
  • NE indicates that the drug was not effective at a concentration >50 micrograms/ml and “-” indicates that the drug was not tested.
  • TABLE 1 Gram Positive S. S. S.saliv- P.acnes P.acnes Drug Code mutans sanguis arius 6922 11828 NA1mF 0.8 0.8 3.1 0.2 0.4 NA1mC 3.1 6.3 50 6.3 6.3 NA2mF NE 0.8 50 0.4 0.4 NA2mC 6.3 6.3 50 6.3 12.5 NA2pC 1.6 6.3 50 6.3 6.3 BPAmF NE NE NE 0.2 0.4 BPAmC NE NE NE 0.2 12.5 BBAmF NE NE NE 0.2 0.8 NA1 50 NE NE 25 NE NA1NpC NE — — 0.4 — NA1pBz NE — — — — NA1OHmF 6.3 — — 3.1 — NA1-2mOMe NE
  • This embodiment illustrates the efficacy of the compounds of the present invention against Streptococcus strains.
  • Str.pn.R was obtained from the Children's Hospital in Buffalo (strain 00-041-0614). It was isolated from the bronchial wash and was found to be beta lactamase positive. The sensitivity of this strain was tested against several known antibiotics. The results indicated that it was sensitive to Clindamycin, Vancomycin, Trovoflox, Rifampin but resistant to penicillin and erythromycin. The efficacy, measured as MIC values, is shown in Table 5.
  • This embodiment describes the sensitivity of various staphylococcus strains to the compounds of the present invention.
  • the staphylococcus species R is a strain 00-045-1209 from the Children's Hospital in Buffalo. It was isolated from the peritoneal cavity (fluid culture) of an individual. It was coagulase negative. The sensitivity of this strain was tested agaisnt several known antibiotics. The results indicated that it was sensitive to vancomycin but resistant to amoxicillin, clindamycin, erythromycin, oxacillin, azithromycin, and cefotaxime. However, this strain was found to be sensitive to the compounds of the present invention with the highest effect being observed with NA1mF (Table 5).
  • the S.aureus R2 species is a strain 00-42-1066 from the Children's Hospital in Buffalo. It was isolated from a wound in an individual. It was coagulase negative. The sensitivity of this strain was tested agaisnt several known antibiotics. The results indicated that it was sensitive to vancomycin but resistant to amoxicillin, clindamycin, erythromycin, oxacillin, azithromycin, and cefotaxime. TABLE 5 Drug Code S. aureus S. species R S.
  • This embodiment illustrates that the antiinflammatory effects of the compounds of the present invention is comparable to those of known antiinflammatory agents such as saliflor (TMF-12).
  • TMF-12 known antiinflammatory agents
  • the TPA mouse ear inflammation assay was used for acute inflammation as described in U.S. Pat. Nos. 5,958,911 and 6,117,859 (incorporated herein by reference).
  • ear biopsies were weighed six hours after treatment with TPA (positive control) and the simultaneous application of a compound of the present invention (NA1mF, NA2mF), TMF-12 or in the absence of TPA (negative control). The results of the experiment are shown in FIG. 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention discloses novel naphthylsalicylanilides of the general formula
Figure US20020065322A1-20020530-C00001
wherein W is a substituted or unsubstituted naphthyl ring. The substitution on W includes replacing one or more —H with —OH, alkyl, O-alkyl, branched alkyl, or cycloalkyl, containing 1-6 carbon atoms or combinations thereof. Y is a substituted or unsubstituted phenyl ring or substituted or unsubstituted naphthyl ring. The substitution for Y includes replacement of one or more —H atoms with CN, CF3, NO2, methoxy, benzoyl, phenoxy, phenoxymethyl or combinations thereof. These compounds are useful as antibacterial against gram negative and gram positive bacteria and as antiinflammatory agents.

Description

  • This application claims priority of U.S. provisional application Ser. No. 60/237,319, filed on Oct. 2, 2000, the disclosure of which is incorporated herein by reference.[0001]
    • FIELD OF INVENTION
  • The present invention relates generally to the field of antimicrobial agents. More particularly, the present invention provides novel naphthylsalicylanilides and a method for the use of these compounds as antimicrobial and antiimflammatory agents. [0002]
    • DISCUSSION OF RELATED ART
  • Several Salicylanilide compounds have been identified as potential antimicrobial agents. Previously, some of these agents have been shown to be effective against microorganisms associated with dental plaques. [0003]
  • U.S. Pat. No. 4,287,191 discloses 5-acylsalicylanilides which are said to be effective antiseptics against a wide range of microorganisms, especially bacteria and the microorganisms prevalent in dental plaque. However, these compounds were not found to be effective against antibiotic resistant bacteria such as [0004] S.mutans. The general structure of these compounds can be represented by the following formula:
    Figure US20020065322A1-20020530-C00002
  • Wherein Z is a substituted phenyl ring, R is a substituted or unsubstituted alkyl or phenyl group and X is —CN, —F, NO[0005] 2, —H, lower alkyl or lower haloalkyl.
  • U.S. Pat. No. 4,358,443 discloses 5-alkylsalicylanilides having the same general formula as above wherein R is a substituted or unsubstituted-alkyl or phenyl group. [0006]
  • U.S. Pat. No. 4,939,132 discloses 5-sulfonylalkylsalicylanilides as antimicrobials having the same general formula as above wherein R is a substituted or unsubstituted alkylsulfonyl group. [0007]
  • U.S. Pat. Nos. 4,742,083 and 5,958,911 disclose antiinflammatory effects of salicylanilides. [0008]
  • Given the constant emergence of antibiotic resistant bacteria, there is an ongoing need for novel antimicrobial agents effective against a wide variety of bacteria. [0009]
    • SUMMARY OF THE INVENTION
  • The present invention provides novel aroylsalicylanilides. In particular, the present invention provides novel 5-naphthylsalicylanilides and describes the antimicrobial effects of these compounds against a wide variety of bacteria. Further, this invention also provides a method of using these compounds for obtaining relief from infections associated with the bacteria. [0010]
  • Accordingly, it is an object of the invention to provide novel naphthylsalicylanilides. [0011]
  • Another object of the present invention is to provide a method for the use of naphthylsalicylanilides as antimicrobial agents. [0012]
  • A yet another object of the present invention is to provide a method for the control of periodontal disease.[0013]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a representation of the effect of naphthylsalicylanilides and TMF-12 on the ear weights in a mouse ear inflammation assay.[0014]
    • DETAILED DESCRIPTION OF THE INVENTION
  • Definitions [0015]
  • By the term “partition coefficient” as used herein for the purposes of specification and claims is meant the log[0016] 10P where P is the ratio of the molar concentrations of the compositions of the composition in octanol-water system. Partition coefficient is a measure of the lipophilic character of the compound. A partition coefficient of 4 therefore means that the ratio of the concentration of the composition in octanol to the concentration in water is 104 or 10,000 to 1.
  • By the term “high lipophilicity” as used herein for the purposes of specification and claims is meant a partition coefficient greater than 4. [0017]
  • By the term “substituted” as used herein for the purposes of specification and claims is meant that one or more hydrogens atoms in the compound is replaced with a carbon and/or nitrogen containing moiety such as, but not limited to, alkyl, O-alkyl, branched alkyl, cycloalkyl (all alkyl groups containing 1-6 carbon atoms), CN, CF[0018] 3, NO2, methoxy, phenoxy, benzoyl, phenoxymethyl and combinations thereof.
  • The present invention is based on the unexpected observation that 5-naphthylsalicylanilides were observed to be more effective antibacterial agents than the 5-acyl or 5-alkyl salicylanilides disclosed in U.S. Pat. Nos. 4,287,191 and 4,358,443. The compounds of the present invention are encompassed by the following formula (designated herein as Formula 100). [0019]
    Figure US20020065322A1-20020530-C00003
  • wherein W is a substituted or unsubstituted naphthyl ring. The substitution on W includes replacing one or more —H with —OH, alkyl, O-alkyl, branched alkyl, or cycloalkyl, containing 1-6 carbon atoms or combinations thereof. Y is a substituted or unsubstituted phenyl ring or substituted or unsubstituted naphthyl ring. The substitution for Y includes replacement of one or more —H atoms with CN, CF[0020] 3, NO2, methoxy, benzoyl, phenoxy, phenoxymethyl or combinations thereof.
  • In one embodiment, wherein Y is substituted or unsubstituted phenyl group, and W is unsubstituted naphthyl group, the compounds of the present invention may be represented by the following formula (Formula 110): [0021]
    Figure US20020065322A1-20020530-C00004
  • Wherein Z represents the substitution on the phenyl ring. Z is preferably an electron withdrawing group and desirably is not strongly hydrophilic or water solublizing. In one embodiment, Z is independently at each location —H, CF[0022] 3, —CN or —NO2. When Z is H at each position, the compound is designated herein as NA1. When Z is —CF3 at the meta position, the compound has the following structure:
    Figure US20020065322A1-20020530-C00005
  • The above compound is referred to herein as NA1mF. This is an α isomer (attachment at the naphthalene 1-position). The β isomer (attachment at the naphthalene 2-position) of this compound is referred to herein as NA2mF. When Z is a —CN group at the meta position, the compound has the following structure. [0023]
    Figure US20020065322A1-20020530-C00006
  • This compound is designated herein as NA1mC(α isomer; attachment at the naphthalene 1-position) or Na2mC (β isomer; attachment at the naphthalene 2-position). When the —CN group is at the para position, the compound is referred to herein as NA1pC (a isomer) or NA2pC (β isomer). Similar isomers for other compounds of the present invention are intended to be within the scope of this invention. [0024]
  • In another embodiment, Z may be a methoxy, phenoxy, benzoyl or phenoxymethyl group. An example when Z is a phenoxymethyl group is as follows. [0025]
    Figure US20020065322A1-20020530-C00007
  • This compound is referred to herein as NA1[0026] —3BnOPh.
  • In another embodiment, the Z substitution is at both the meta positions. An example of a disubstituted compound is as follows, designated herein as NA1mF2. [0027]
    Figure US20020065322A1-20020530-C00008
  • In another embodiment, Y is an unsubstituted or substituted naphthyl ring. An example of a compound when Y is a substituted naphthyl ring is as follows (designated as NA1NpC). [0028]
    Figure US20020065322A1-20020530-C00009
  • In another embodiment, the naphthyl group W of the naphthylsalicylanilides of Formula 100 may substituted. An example of such a substitution is wherein a —H is substituted by —OH. [0029]
    Figure US20020065322A1-20020530-C00010
  • This compound is referred to herein as NA10HmF. [0030]
  • The compounds of the present invention can be synthesized by a two-step process where the first step prepares the ester to be used for all similar (such as 1-naphthoyl) derivatives with the same aroyl group. In the second step the desired anilide is prepared by reacting the ester with the aniline or aniline derivative. [0031]
  • An advantage of the compounds of the present invention is that they have unexpectedly higher potency than the salicylanilides described previously (U.S. Pat. No. 4,287,191; 4,358,443 and 4,939,132). In the compounds of the present invention, the 5-naphthyl groups are connected to the salicylanilides via a carbonyl group. [0032]
  • The introduction of the naphthyl group at the 5-position renders them effective against a wide range of bacteria. Thus, the compounds of the present invention have been found to be effective against both gram positive and gram negative bacteria. These gram positive bacteria include, but are not limited to, [0033] Streptococcus mutans, Streptococcus sanguis, Micrococcus luteus, Streptococcus salivarius, Propionibacterium acnes, Actinomyces viscosus, Staphlococcus aureus, Lactobacillus rhamnosus (casei) 7469. The gram negative bacteria include, but are not limited to, Salmonella, Fusobacterium nucleatum 25586, Actinobacillus actinomycetemcomitans (Aa) Y4, Escherichia coli, Porphyromonas gingivalis, Salmonella cholerasuis (Sal. chsuis), Bacteroides fragilis and Citrobacter.
  • Since these compounds are highly lipophilic, they are insoluble in H[0034] 2O . However, and quite unexpectedly, these compounds were found to be soluble in aqueous solutions of both anionic and non-ionic detergents at concentrations routinely used in topical applications. This property of these compounds makes them suitable as topical antimicrobial and antiinflammatory agents.
  • Accordingly, the compounds of this invention may be incorporated into formulations for topical application. Such applications include, but are not limited to, topical formulations the treatment of infection of mouth, skin, scalp, ear, nose, eyes, vagina and rectum. The infections treated by these compounds includes various disorders including gingivitis and acne. [0035]
  • The compounds of this invention may also be used as topical antimicrobial or antiinflammatory agents for veterinary use for the relief of infections in various conditions including gingivitis, conjunctivitis and arthritis. The formulations can be applied to, without limitation, mouth, skin, scalp, ear, nose, eyes, vagina and rectum. [0036]
  • The method in accordance with the present invention for the relief of infection or inflammation comprises contacting the affected area with the compounds of this invention in a pharmaceutically acceptable carrier containing alcohols, nonionic or ionic detergent. Such a carrier base may be selected from the group consisting of petroleum jelly, lanolin, paraffin wax, alkanols and mixtures thereof. By using a base such as lanolin or petroleum jelly, a spreadable formulation is obtained and by using a base such as paraffin wax, a stick for topical application is obtained. In addition, the compounds of this invention may also be incorporated into liquid carriers containing alcohols, non-ionic or ionic detergents. Thus, ethanol, the non-ionic detergent, Tween 80™ and the anionic detergent, sodium lauryl sulfate (SLS) may be used. [0037]
  • The above compounds can be used as antimicrobial or antiinflammatory agents in mammals, particularly humans, by topical application of formulations containing the compounds of the present invention. These compounds can be used, without limitation, in tooth pastes, mouth rinses, soaps, shampoos, skin ointments, skin lotions, eye ointments, eye drops, ear drops, and nasal drops. [0038]
  • In addition to the effect of the present compounds on the bacteria associated with dental plaques, another unexpected observation is that these compounds were also found to be effective against bacteria other than those associated with the oral cavity. Accordingly, the drug formulations of the present invention can be used for relief of systemic infections. Thus, these compounds can be used with pharmaceutical carriers suitable for delivery of lipophilic drugs such as, but not limited to, liposomal formulations or aerosols. [0039]
  • Liposomes are phospholipid vesicles which form closed fluid filled spheres when dispersed in aqueous solutions. Phopholipid molecules are polar molecules having a hydrophilic head toward the aqueous side and two hydrophobic tails made of fatty acid chains. At sufficient concentrations, the phospholipid molecules organize into micells with polar heads point toward the aqueous medium and the fatty acid chains point toward the interior of the micelle. Various types of liposomal preparation techniques are described in U.S. Pat. No. 5,958,449, the disclosure of which is incorporated herein by reference. Liposomes may be delivered via routes such as intravenous, subcutaneous and topical. The liposomes may also be directed to target areas with the use of specific targeting agents such as by incorporating specific recognition molecules in the liposomes. [0040]
  • Another method of delivery of the formulations of compounds of the present invention, including liposomal formulations, is via aerosols. Appropriate concentrations for any particular mode of delivery and application will vary with the condition being treated. Determination of such concentrations are well within the purview of one skilled in the art. [0041]
  • The following examples illustrate the invention. [0042]
    • EXAMPLE 1
  • This example illustrates the synthesis of 2-Hydroxy-5-(naphthalene-1-carbonyl)-N-phenyl-benzamide designated herein as NA1 in a two-step process. [0043]
  • Synthesis of 2-Hydroxy-5-(Naphthalene-1-carbonyl)-benzoic Acid Phenyl Ester [0044]
  • The reaction vessel was a 500 ml three neck round bottom pyrex flask fitted with a 250 mL addition funnel, thermometer, a reflux condenser, and a stirrer. Aluminum chloride (7.98g, 59.8 mmole) and 225 mL of chloroform were added into the round bottom flask and then this stirred suspension was cooled to 5° C. with an external ice-bath. Phenyl salicylate (5.83 g, 27.2 mmole) and naphthalene-l-carbonyl chloride (4.91 mL, 6.21 g, 32.6 mmole) were combined together with 130 mL of chloroform and added dropwise over a hour and half to the stirred suspension. Upon this addition color changes were observed from colorless to light yellow then dark green and finally to dark brown. The temperature was maintained at 5-15° C. during the addition period. Following the addition the reaction mixture was heated to reflux for 48 hours and then allowed to stand at 22° C. for eight hours. [0045]
  • The reaction mixture was slowly added to a stirred slurry of 50 mL of crushed ice to which 125 mL of 12N HCl had been added. The organic layer was isolated in a 1-liter separatory funnel and was washed 5 times with distilled water. Purity was checked on TLC (silica gel plate) and the solvent used was 1:1 ratio of CH[0046] 2Cl2 and hexane. Three spots were observed on TLC, the phenyl ester was on the top and the product spot was in the middle.
  • Purification was achieved by using flash column chromatography on silica gel with the same solvent system described above. There resulted 3.75 g (31%) of the desired product phenyl ester as a white solid, mp 82-84° C. 'H NMR (300 MHz, CDCI,) δ7.276 (d, J=9.0 Hz, 1H, ArH), 7.357 (d, J=8.1 Hz, 2H, ArH), 7.459 (m, 2H, ArH), 7.617 (t, 2H, ArH), 7.732 (m, 5H, ArH), 8.120 (m, TH, ArH), 8.206 (m, 3H, ArH), 8.903 (d, J=2.1 Hz, 1H, ArH), 11.254 (s, 1H, OH, D[0047] 2O exchangeable) IR (KBr) v 1652.9, 1566.1, 1199.65 cm−1.
  • Synthesis of 2-Hydroxy-5-(naphthalene-1-carbonyl)-N-phenyl-benzamide [0048]
  • Hydrogen chloride gas was slowly bubbled into a solution of 300 mg of aniline in 5 mL of isopropyl ether until the solution was saturated with hydrogen chloride. The resulting white precipitate of aniline hydrochloride salt was collected and dried. 0.0501 g of this salt, together with 1.50 g, (4.07 mmole) of the phenyl ester, described above, and 0.459 mL (5.04 mmole) of aniline, was placed in a 50 mL round bottom flask fitted with a distilling head connected with dry argon gas. The reaction mixture was first purged with dry argon gas for 30 minutes then the temperature was raised to 90° C. with an external oil bath to melt the ester. Finally, the temperature was raised to 170° C. and was maintained at 170° C. for 12 hours. During this period the TLC was checked several times to make sure the reaction was completed. Dry argon gas purge was used during the heating period. [0049]
  • Purity was checked by using TLC (silica gel plate) with 10:1 hexane and ethyl acetate. Four spots were observed on TLC, the target compound was the second spot from the bottom just a bit higher than aniline spot, and the color was light yellow. [0050]
  • Purification was achieved by using flash column chromatography on silica gel with 10:1 hexane to ethyl acetate solvent system. The product was collected and dried to give 0.398 g (27%) of light yellow solid, mp 100-104° C. 'H NMR (300 MHz, DMSO-d[0051] 6) δ6.846 (d, J=7.5 Hz, 2H, ArH), 6.910 (m, 2H, ArH), 7.139 (m, 3H, ArH), 7.262 (m, 2H, ArH), 7.492 (m, 3H, ArH), 7.640 (m, 2H, ArH), 7.725 (m, 3H, ArH), 8.057 (m, 2H, ArH), 8.441 (s, 1H, ArH), 9.507 (s, 1H, OH, D2O exchangeable), 10.617 (s, 1H, NH, D2O exchangeable) IR (KBr) v 3059.8, 1642.2, 1593.1 cmr−1.
    • EXAMPLE 2
  • This embodiment demonstrates the effectiveness of the compounds of the present invention against gram positive bacteria. The MIC's for the compounds were determined by a modified microdilution tube dilution method described in “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically” (National Committee for Clinical Laboratory Standards Approved Standards, 1997, NCCLS document M7-A4). In general the modifications were made because of the unique growth requirements for the fastidious oral organisms and for those bacteria that require anaerobic conditions. Reference is also made to “Methods for Antimicrobial Susceptibility of Anaerobic Bacteria” (National Committee for Clinical Laboratory Standards Approved Standards, 1997, NCCLS document M11-A4). [0052]
  • Briefly, the methods were as follows. Cultures were grown for 18-24hrs (aerobic bacteria) or 48-72 hrs (anaerobic bacteria) in the appropriate medium. For aerobic bacteria full strength brain heart infusion medium (BHI, Difco) was used. For anaerobic bacteria, half strength BHI (18.5 g/L) was supplemented by adding yeast extract (10 g/L), hemin (0.29 mL of a stock solution containing 0.1 g/200 mL dH[0053] 2O) and menadione (15 mL of a stock solution containing 0.15 mL in 30 mL 95o EtOH) was used. Initial cultures were diluted to approximately 1×108 CFU/mL for use as an inoculum. Each assay received 10 μL of the inoculum. The drugs were prepared from a stock solution contained in dimethyl sulfoxide (DMSO) and diluted into the culture medium. Final concentrations of the drugs ranged from 50 to 0.05 μg/assay. The tests were run in duplicate and were incubated appropriately with regard to oxygen requirements for 24 to 48hrs as required. Anaerobic incubation was an atmosphere of 5% C02, 10% H2, with the balance N2. The lowest concentration of an antimicrobial agent at which no visible growth is noted was referred to as the MIC. 5 The compounds of the present invention used in this example NA1mF, NA1mC, NA2mF, NA2mC, NA1pC, NA1, NA1NpC, NA1pBz, NA10HmF, NA1—3BnOPh, NA1mOPh and NA1mF2 have been described above. NA1pBz is a naphthylsalicylanilide of Formula 110 wherein Z is benzoyl at the para position. NA1mOPh has the structure of Formula 110 wherein Z is phenoxy at the meta position and NA1-2mOMe has the structure of Formula 110 wherein Z is —OCH3 at both the meta positions. The structure of TMF-12 is described in U.S. Pat. No. 6,117,859. BPAmF, BPAmC and BBAmF are substituted or unsubstituted alkylsalicylanilides described in U.S. Pat. No. 4,287,191. Their structures are also provided below
  • BPAmF has the following structure: [0054]
    Figure US20020065322A1-20020530-C00011
  • BPAmC has the following structure: [0055]
    Figure US20020065322A1-20020530-C00012
  • BBAmF has the following structure: [0056]
    Figure US20020065322A1-20020530-C00013
  • In Tables 1-5, NE indicates that the drug was not effective at a concentration >50 micrograms/ml and “-” indicates that the drug was not tested. [0057]
    TABLE 1
    Gram Positive
    S. S. S.saliv- P.acnes P.acnes
    Drug Code mutans sanguis arius 6922 11828
    NA1mF 0.8 0.8   3.1 0.2 0.4
    NA1mC 3.1 6.3 50 6.3 6.3
    NA2mF NE 0.8 50 0.4 0.4
    NA2mC 6.3 6.3 50 6.3 12.5 
    NA2pC 1.6 6.3 50 6.3 6.3
    BPAmF NE NE NE 0.2 0.4
    BPAmC NE NE NE 0.2 12.5 
    BBAmF NE NE NE 0.2 0.8
    NA1 50   NE NE 25   NE
    NA1NpC NE — — 0.4 —
    NA1pBz NE — — NE —
    NA1OHmF 6.3 — — 3.1 —
    NA1-2mOMe NE — — NE —
    NA1_3BnOP NE — — NE —
    NA1mOPh NE — — NE —
    NA1mF2 1.6 — — 0.4 —
    TMF-12 NE 12.5  NE 0.4 0.2
  • [0058]
    TABLE 2
    Gram Positive
    Lact
    Drug Code A. viscosus S. aureus 7469 M. luteus
    NA1mF <0.1  1.6/3.1  0.4 0.8
    NA1mC 3.2 6.3/12.5 3.1 3.1
    NA2mF NE NE 1.6 0.8
    NA2mC 1.6 NE 12.5 3.1
    NA2pC 1.6 6.3 6.3 3.1
    BPAmF NE NE 6.3 3.1
    BPAmC NE NE 12.5 3.1
    BBAmF NE NE 6.3 3.1
    NA1 3.1 50 — —
    NA1NpC 0.8 NE — —
    NA1pBz NE NE — —
    NA1OHmF 0.8 NE — —
    NA1-2mOMe NE NE — —
    NA1_3BnOP 6.3 NE — —
    NA1mOPh NE NE — —
    NAmF2 0.8 NE — —
    TMF-12 1.6 NE 3.1 0.8
    • EXAMPLE 3
  • This embodiment demonstrates that effectiveness of the compounds of the present invention against gram negative bacteria. The method used was the same as described in Example 1. [0059]
    TABLE 3
    Gram Negative
    Fuso. P.ging Pg B.frag-
    Drug Code 25586 Aa Y4 381 53977 ilis
    NA1mF 3.1 3.1 <0.1  <0.1  3.1
    NA1mC 2.5 6.3 0.4 0.8 NE
    NA2mF NE NE <0.4  <0.4  NE
    NA2mC NE NE 0.8 0.8 3.1
    NA2pC 12.5  6.3 0.4 0.4 3.1
    BPAmF NE NE <0.4  <0.4  50  
    BPAmC NE NE <0.4  <0.4  50  
    BBAmF NE NE <0.4  <0.4  NE
    NA1 — — 1.6 — —
    NA1NpC — — 0.2 — —
    NA1pBz — — NE — —
    NA1OHmF — — 0.8 — —
    NA1-2mOMe — — NE — —
    NA1_3BnOP — — 3.1 — —
    NA1mOPh — — NE — —
    NAmF2 — — 0.2 — —
    TMF-12 NE NE 0.4 0.4 NE
  • [0060]
    TABLE 4
    Gram negative
    S.pyo S.pyo S.pyo Str.pn Str.pn Str.pn
    Drug Code 51339 49399 19615 6303 6301 6305
    NA1mF 1.6  0.78 0.63 0.18 0.78 0.39
    NA1mC 12.5  12.5  25    0.18 1.56 1.56
    NA2mF 0.4 3.2 NE 0.18 0.78 1.56
    NA2mC NE NE NE 6.78 1.56 0.39
    NA2pC 3.2 3.2 NE 0.18 0.78 0.78
    BPAmF 6.3 6.3 NE 0.18 1.56 0.78
    BPAmC NE NE NE 0.18 0.78 0.78
    BBAmF 6.3 6.3 NE 0.18 0.78 0.39
    NA1 — 12.5  — — — —
    NA1NpC — 6.3 — — — —
    NA1pBz — NE — — — —
    NA1OHmF — 3.1 — — — —
    NA1-2mOMe — NE — — — —
    NA1_3BnOP — 50   — — — —
    NA1mOPh — NE — — — —
    NAmF2 — 1.6 — — — —
    TMF-12  0.32 0.8 0.32 0.78 0.39 0.78
  • None of the drugs tested were found to be effective against Salmonella, [0061] E.coli, Sal.chsuis and Citrobacter even at concentrations greater than 50 micrograms/mL. NE denotes a lack of a detectable effect at 50 micrograms per ml.
    • EXAMPLE 4
  • This embodiment illustrates the efficacy of the compounds of the present invention against Streptococcus strains. One of the strains, Str.pn.R was obtained from the Children's Hospital in Buffalo (strain 00-041-0614). It was isolated from the bronchial wash and was found to be beta lactamase positive. The sensitivity of this strain was tested against several known antibiotics. The results indicated that it was sensitive to Clindamycin, Vancomycin, Trovoflox, Rifampin but resistant to penicillin and erythromycin. The efficacy, measured as MIC values, is shown in Table 5. [0062]
    TABLE 5
    Mean Streptococcus MIC values
    Drug Code Str..pyo Str.pn Str.pn.R
    NA1mF 1.0 0.45 0.78
    NA1mC 16.67 1.10 12.5
    NA2mF — 0.84 0.78
    NA2mC NE 0.91 6.25
    NA2pC — 0.58 3.12
    BPAmF — 0.84 NE
    BPAmC — 0.58 NE
    BBAmF — 0.45 NE
    TMF-12 0.47 0.65 0.78
    • EXAMPLE 5
  • This embodiment describes the sensitivity of various staphylococcus strains to the compounds of the present invention. The staphylococcus species R is a strain 00-045-1209 from the Children's Hospital in Buffalo. It was isolated from the peritoneal cavity (fluid culture) of an individual. It was coagulase negative. The sensitivity of this strain was tested agaisnt several known antibiotics. The results indicated that it was sensitive to vancomycin but resistant to amoxicillin, clindamycin, erythromycin, oxacillin, azithromycin, and cefotaxime. However, this strain was found to be sensitive to the compounds of the present invention with the highest effect being observed with NA1mF (Table 5). [0063]
  • The [0064] S.aureus R2 species is a strain 00-42-1066 from the Children's Hospital in Buffalo. It was isolated from a wound in an individual. It was coagulase negative. The sensitivity of this strain was tested agaisnt several known antibiotics. The results indicated that it was sensitive to vancomycin but resistant to amoxicillin, clindamycin, erythromycin, oxacillin, azithromycin, and cefotaxime.
    TABLE 5
    Drug Code S. aureus S. species R S. aureus R2
    NA1mF  3.1  1.6  1.6
    NA1mC 12.5 25.0  6.3
    NA2mF NE 25.0 25.0
    NA2mC NE NE NE
    NA2pC  6.3 12.5 NE
    BPAmF NE NE NE
    BPAmC NE NE NE
    BBAmF NE NE NE
    TMF NE NE NE
    • EXAMPLE 6
  • This embodiment illustrates that the antiinflammatory effects of the compounds of the present invention is comparable to those of known antiinflammatory agents such as saliflor (TMF-12). For this illustration, the TPA mouse ear inflammation assay was used for acute inflammation as described in U.S. Pat. Nos. 5,958,911 and 6,117,859 (incorporated herein by reference). To quantitate inflammation, ear biopsies were weighed six hours after treatment with TPA (positive control) and the simultaneous application of a compound of the present invention (NA1mF, NA2mF), TMF-12 or in the absence of TPA (negative control). The results of the experiment are shown in FIG. 1. [0065]
  • Various embodiments are presented herein for illustrative purposes and are not to be construed as restrictive. Modifications of the embodiments presented herein that are obvious to those skilled in the art are intended to be within the scope of the invention and the claims. [0066]

Claims (27)

We claim:
1. A compound having the formula
Figure US20020065322A1-20020530-C00014
wherein W is a substituted or unsubstituted naphthyl ring, wherein the substitution on the naphthyl ring W consists of replacing one or more —H with a moiety selected from the group consisting of —OH, alkyl containing 1-6 carbon atoms, O-alkyl containing 1-6 carbon atoms, branched alkyl containing 1-6 carbon atoms, cycloalkyl containing 1-6 carbon atoms and combinations thereof, wherein Y is selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted naphthyl, wherein the substitution on the phenyl or naphthyl ring Y consists of replacing one or more —H with a moiety selected from the group consisting of cyano, trifluoromethyl, nitro, methoxy, phenoxy, benzoyl, phenoxymethyl and combinations thereof.
2. The compound of claim 1 having the following structure.
Figure US20020065322A1-20020530-C00015
wherein Z is independently at each position selected from the group consisting of —H, —CF3, —CN, —NO2 methoxy, phenoxy, benzoyl and phenoxymethyl; or an isomer thereof.
3. The compound of claim 2, wherein Z is —CF3 at the meta or para position.
4. The compound of claim 2, wherein Z is —CN at the meta or para position.
5. The compound of claim 2, wherein Z is —NO2 at the meta or para position.
6. The compound of claim 2, wherein Z is a methoxy group at the para or meta position.
7. The compound of claim 2, wherein Z is phenoxy group at the meta or para position.
8. The compound of claim 2, wherein Z is benzoyl group at the meta or para position.
9. The compound of claim 2, wherein Z is phenoxymethyl at the meta or para position.
10. The compound of claim 2, wherein Z is CF3 at both the meta positions.
11. The compound of claim 1, having the following structure
Figure US20020065322A1-20020530-C00016
12. The compound of claim 1 having the following structure
Figure US20020065322A1-20020530-C00017
13. The compound of claim 1 having the following structure
Figure US20020065322A1-20020530-C00018
14. A method of treating a bacterial infection in an individual comprising contacting the infected area with a therapeutically effective amount of a compound of the following structure
Figure US20020065322A1-20020530-C00019
wherein W is a substituted or unsubstituted naphthyl ring, wherein the substitution on the naphthyl ring W consists of replacing one or more —H with —OH, wherein Y is selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted naphthyl, wherein the substitution on the phenyl or naphthyl ring Y consists of replacing one or more —H with a moiety selected from the group consisting of cyano, trifluoromethyl, nitro, phenoxymethyl and combinations thereof.
15. The method of claim 14, wherein the compound has following structure
Figure US20020065322A1-20020530-C00020
or an isomer thereof.
16. The method of claim 15, wherein Z is —CN at the meta or para position.
17. The method of claim 15, wherein Z is —NO2 at the meta or para position.
18. The method of claim 15, wherein Z is —CF3 at the meta or para position.
19. The method of claim 15, wherein Z is phenoxymethyl at the meta or para position.
20. The method of claim 14, wherein the compound has the following structure
Figure US20020065322A1-20020530-C00021
21. The method of claim 14, wherein the compound has the following structure
Figure US20020065322A1-20020530-C00022
22. The method of claim 14, wherein the compound has the following structure
Figure US20020065322A1-20020530-C00023
23. The method of claim 14, wherein the bacterial infection is caused by organisms selected from the group consisting of gram positive bacteria, gram negative bacteria and combinations thereof.
24. The method of claim 23, wherein the gram positive bacteria are selected from the group consisting of S. mutans, S.sanguis, S.salivarius, P.acnes, A.viscosus, S.aureus, L. rhamnosus.
25. The method of claim 23, wherein the gram negative bacteria are selected from the group consisting of Sal. chsuis, Fuso. nucleatum, A. actinomycetemcomitans, E. coli, P.gingivalis, B. fragilis and Citrobacter.
26. A method of treating inflammation in an individual comprising contacting the affected area with an amount sufficient to ameliorate the inflammatory condition, of a compound of the following formula:
Figure US20020065322A1-20020530-C00024
wherein W is a substituted or unsubstituted naphthyl ring, wherein the substitution on the naphthyl ring w consists of replacing one or more —H with a moiety selected from the group consisting of —OH, alkyl containing 1-6 carbon atoms, O-alkyl containing 1-6 carbon atoms, branched alkyl containing 1-6 carbon atoms, cycloalkyl containing 1-6 carbon atoms and combinations thereof, wherein Y is selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted naphthyl, wherein the substitution on the phenyl or naphthyl ring Y consists of replacing one or more —H with a moiety selected from the group consisting of cyano, trifluoromethyl, nitro, methoxy, phenoxy, benzoyl, phenoxymethyl and combinations thereof.
27. The method of claim 26, wherein the compound has the following formula:
Figure US20020065322A1-20020530-C00025
or an isomer thereof.
US09/969,071 2000-10-02 2001-10-02 Naphthylsalicylanilides as antimicrobial and antiinflammatory agents Expired - Lifetime US6407288B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/969,071 US6407288B1 (en) 2000-10-02 2001-10-02 Naphthylsalicylanilides as antimicrobial and antiinflammatory agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23731900P 2000-10-02 2000-10-02
US09/969,071 US6407288B1 (en) 2000-10-02 2001-10-02 Naphthylsalicylanilides as antimicrobial and antiinflammatory agents

Publications (2)

Publication Number Publication Date
US20020065322A1 true US20020065322A1 (en) 2002-05-30
US6407288B1 US6407288B1 (en) 2002-06-18

Family

ID=22893236

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/969,071 Expired - Lifetime US6407288B1 (en) 2000-10-02 2001-10-02 Naphthylsalicylanilides as antimicrobial and antiinflammatory agents

Country Status (11)

Country Link
US (1) US6407288B1 (en)
EP (1) EP1328507B1 (en)
JP (1) JP4086658B2 (en)
CN (1) CN1249019C (en)
AT (1) ATE356798T1 (en)
AU (1) AU2002211842A1 (en)
CA (1) CA2424396C (en)
DE (1) DE60127285T2 (en)
DK (1) DK1328507T3 (en)
MX (1) MXPA03002891A (en)
WO (1) WO2002028819A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319112B2 (en) 2000-07-14 2008-01-15 The Procter & Gamble Co. Non-halogenated antibacterial agents and processes for making same
US7709026B2 (en) * 2001-10-29 2010-05-04 Columbia Laboratories, Inc. Low concentration of peroxide for treating or preventing vaginal infections
EA008622B1 (en) * 2002-06-05 2007-06-29 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Immunity-related protein kinase inhibitors
CA2487891A1 (en) * 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Inhibitors against the activation of ap-1 and nfat
CA2488367A1 (en) * 2002-06-06 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Antiallergic agents
TW200406198A (en) 2002-06-06 2004-05-01 Inst Med Molecular Design Inc O-substituted hydroxyaryl derivatives
EP1535610A4 (en) * 2002-06-10 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC AGENT TO TREAT CANCER
EP1535609A4 (en) * 2002-06-10 2009-01-07 Inst Med Molecular Design Inc NF-KB ACTIVATION INHIBITORS
CN1681487A (en) 2002-07-15 2005-10-12 美瑞德生物工程公司 Compounds, compositions, and methods for employing the same
MXPA05002977A (en) * 2002-09-18 2005-06-22 Procter & Gamble Non-halogenated antibacterial agents and processes for making same.
CN104546857B (en) * 2013-10-18 2017-01-04 北京北科德源生物医药科技有限公司 Antibacterial application of compound naphthoenequinazolone
EP3220919A4 (en) * 2014-11-17 2018-07-18 Victoria Link Limited Antibacterial compounds
CN114727975B (en) * 2019-11-18 2024-10-29 加利福尼亚大学董事会 Dual androgen receptor/AKR 1C3 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287191A (en) * 1980-04-14 1981-09-01 The Research Foundation Of State University Of New York Novel salicylanilides and microbiocidal compositions and uses thereof
US4358443A (en) * 1980-04-14 1982-11-09 The Research Foundation Of State University Of New York Method and composition for controlling the growth of microorganisms
US4742083A (en) * 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4939132A (en) * 1985-04-15 1990-07-03 The Research Foundation Of State University Of New York Novel 5-alkylsulfonylsalicylanilides and microbiocidal compositions for controlling the growth of microorganisms
US5958911A (en) * 1996-11-05 1999-09-28 The Research Foundation Of State University Of New York Method of relieving inflammation by using 5-alkylsulfonylsalicylanilides

Also Published As

Publication number Publication date
MXPA03002891A (en) 2003-10-15
DE60127285D1 (en) 2007-04-26
JP2004510756A (en) 2004-04-08
CN1468210A (en) 2004-01-14
CN1249019C (en) 2006-04-05
EP1328507A1 (en) 2003-07-23
WO2002028819A1 (en) 2002-04-11
AU2002211842A1 (en) 2002-04-15
DK1328507T3 (en) 2007-07-02
US6407288B1 (en) 2002-06-18
EP1328507B1 (en) 2007-03-14
JP4086658B2 (en) 2008-05-14
DE60127285T2 (en) 2007-12-20
CA2424396A1 (en) 2002-04-11
EP1328507A4 (en) 2005-07-27
ATE356798T1 (en) 2007-04-15
CA2424396C (en) 2009-12-08

Similar Documents

Publication Publication Date Title
US6407288B1 (en) Naphthylsalicylanilides as antimicrobial and antiinflammatory agents
JP5037436B2 (en) 9-Substituted minocycline compounds
JP2002501026A (en) Pharmaceutically active compounds and uses thereof
US7696358B2 (en) Five-membered heterocyclyl tetracycline compounds and methods of use thereof
DE60129116T2 (en) 7- AND 9-CARBAMATE, UREA, THIN, FA, THIOCARBAMATE AND HETEROARYL-AMINO SUBSTITUTED TETRACYCLIN COMPOUNDS
US8012951B2 (en) 7-N-substituted phenyl tetracycline compounds
EP0799833B1 (en) Erythromycin derivatives, their production and their use as medicaments
JP2003533504A (en) 7-substituted fused ring tetracycline compound
JP2013151540A (en) Substituted tetracycline compounds for treatment of malaria
JP2003523963A (en) Tetracycline compounds for the treatment of Cryptosporidium parvum-related diseases
DE3872937T2 (en) BENZOYLAMINOPHENOXYBUTTERIC ACID DERIVATIVES.
EA013835B1 (en) Substituted tetracycline compounds (variants) a pharmaceutical composition and a method for the treatment and a method for treating a tetracycline responsive state in a subject
JP2004502750A (en) 7,8 and 9-substituted tetracycline compounds
DE3851262T2 (en) Benzoylaminophenoxybutyric acid derivatives.
US4299845A (en) Dermatological compositions and methods of use therefor
SE470379B (en) New retinoic acid esters of antibiotics, their preparation process and pharmaceutical and cosmetic compositions containing them
HU214317B (en) Process for preparing hydorxyalkane carboxylic acide derivative and pharmaceutical compositions containing the said compounds
US6423707B1 (en) Nitroimidazole ester analogues and therapeutic applications
CN107982256B (en) Use of 2-aminoimidazole derivatives in the preparation of active drugs for inhibiting bacterial biofilms
DE69519581T2 (en) GUANIDYLMETHYL CYCLOHEXANCARBONIC ACID ESTER DERIVATIVES
DE69207182T2 (en) ANTITUMOR ANTHRACENE DERIVATIVES
JP6664408B2 (en) Compounds that are analogs of squalamine used as antimicrobial agents
JP3156212B2 (en) Novel pharmaceutical use of bilobalide and its derivatives and pharmaceutical compositions adapted for this use
JPWO1996006825A1 (en) Guanidinomethylcyclohexanecarboxylic acid ester derivatives
US3761526A (en) Aryl and cycloalkyl substituted naphthols

Legal Events

Date Code Title Description
AS Assignment

Owner name: RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YOR

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COBURN, ROBERT A.;EVANS, RICHARD T.;GENCO, ROBERT J.;REEL/FRAME:012608/0605;SIGNING DATES FROM 20020108 TO 20020116

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12